Big Pharma: Biotech partnering will shine amid financial downturn
The difficult financial landscape may have dampened biopharma M&A but biotech partnering remains robust and crucial to bring innovation to industry, say Roche and Novartis. The last two years saw some of the lowest levels of M&A in the pharma space since the 2008 financial crash. Meanwhil ...
Patient advocacy group Myeloma UK believes supply issues have caused Johnson & Johnson to not progress its CAR-T cell treatment Carvykti (cil ...
Great Ormond Street Hospital (GOSH) has agreed to manufacture Leucid Bio’s lead asset, LEU011 at the Zayed Center for Research in London, UK.
...
Bispecific antibodies that mirror the natural biology of immune T-cells are the key to a new generation of cancer therapies, according to Regener ...
The facility will boast 180,000 liters of bioreactor capacity, bringing Samsung Biologics’s total capacity in Songdo, Korea to 784,000 liters.
...
Recent Tweets
-
To everyone at #BiotechWeekBoston - thanks for a great event & see you next year!
6 months ago
-
@Dan5tanton hosting BioProcess Insider’s State of the Industry chat at the spotlight theater here at #BWB2022 https://t.co/UBCZCf1Jng
6 months ago
-
@ADaviesDHCG I couldn’t find a seat, it was so busy! A great talk with some really interesting and helpful talks ma… https://t.co/5b3mjes9tb
6 months ago
-
@ADaviesDHCG on stage at the Spotlight Theater discussing CGT capacity & demand #BWB2022 https://t.co/d5T0KYm7mp
6 months ago
